Moreover, the PXR antagonists andPROTAC degrader downregulate the expression of several key genes involvedin gluconeogenesis, cholesterol homeostasis, bile acid synthesis,and proliferation in hepatocyte cells, suggesting their potentialtherapeutic applications for metabolic diseases. This evidence concerns the gene NR1I2 and metabolic disease.